Solara Active Peer Comparison

NSE: SOLARA | BSE: 541540

₹629.75

₹-8.40 (-1.32%)

As on 03-Nov-2026IST

Market cap

₹3,037 Cr

Revenue (TTM)

₹1,535 Cr

P/E Ratio

82.2

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,037	37,611	24,935	18,202	12,866
Revenue (₹ Cr)	1,535	10,234	2,307	2,684	1,170
Net Profit (₹ Cr)	36.94	1,092.67	452.55	669.74	279.64
Net Margin (%)	2.39	10.67	19.31	24.24	22.94
RoE (%)	3.52	21.65	23.18	19.79	13.92
Price to Earnings	82.21	34.40	55.24	27.18	45.55
Price-To-Book	2.11	7.19	12.39	5.01	6.20

Income Statement (₹ Cr)

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	1,535.23	10,234.10	2,307.19	2,684.41	1,170.41
Total Income	1,543.15	10,245.27	2,343.69	2,763.43	1,218.73
Total Expenditure	1,301.42	8,141.47	1,602.28	1,761.70	766.14
EBITDA	233.81	2,092.63	704.92	922.70	404.27
Depreciation	104.96	430.12	104.34	82.27	74.77
EBIT	128.85	1,662.51	600.57	840.44	329.50
Interest	89.44	151.49	28.27	5.42	0.24
Other Income	7.92	11.17	36.50	79.02	48.32
Exceptional Items	-10.39	-27.85	0.00	-25.66	-3.28
Profit before Tax	36.94	1,494.35	608.80	888.39	374.31
Provision for Tax	0.00	401.68	156.25	218.65	94.68
Profit after Tax	36.94	1,092.67	452.55	669.74	279.64

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,436.09	5,344.04	2,029.71	3,631.29	2,075.76
Minority Interest	0.00	0.82	0.00	0.00	3.07
Non-Current Liabilities	249.58	980.81	381.27	146.95	53.38
Current Liabilities	765.79	3,838.93	618.58	563.70	201.71
Total Liabilities	2,332.59	9,514.48	2,930.14	4,157.10	2,231.79

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,355.21	3,542.74	1,471.67	1,454.42	980.16
Current Assets	1,008.80	6,027.59	1,389.85	2,864.85	1,290.68
Total Assets	2,332.59	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	664.54	1,204.08	196.61	0.00	0.00
Net Current Assets	243.01	2,188.66	771.28	2,301.15	1,088.97
Contingent Liabilities	563.73	258.92	13.18	4.82	3.76

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	152.91	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-98.83	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-53.55	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	0.53	93.92	-56.08	-69.08	11.28

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	4.61	25.25	27.50	24.61	18.04
ROE (%)	3.52	21.65	23.18	19.79	13.92
ROA (%)	1.56	11.17	16.27	16.78	12.86
EBIT Margin (%)	8.39	16.24	26.03	31.31	28.15
Net Margin (%)	2.39	10.67	19.31	24.24	22.94
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	27.30	21.12	50.46	8.19	4.02
EBIT Growth (%)	31.63	32.84	138.53	24.77	-11.95
Net Profit Growth (%)	476.29	33.33	88.45	26.27	-12.44
EPS Growth (%)	635.43	38.63	131.13	29.79	-12.06
Book Value Growth (%)	14.35	11.36	22.95	18.43	11.27

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	64.15	33.75	55.10	26.36	45.16
Price / Book Value	2.11	7.19	12.34	5.01	6.20
Dividend Yield (%)	0.00	0.18	0.17	0.34	0.61
EV/EBITDA	15.60	18.48	35.15	18.88	30.80
Market Cap (₹ Cr)	1,891.93	30,257.56	15,412.11	11,956.86	10,627.92

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.12	0.10	0.10	0.00	0.00
Short term debt to equity ratio	0.40	0.16	--	--	--
Current Ratio	1.32	1.57	2.25	5.08	6.40
Quick Ratio	0.84	0.92	1.35	3.69	4.43
Interest Coverage	1.41	10.86	22.53	165.03	1,593.82

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	32.97	26.69	12.76	36.81	35.24
Asset Turnover	0.65	1.05	0.83	0.67	0.54
Receivable days	98.65	88.68	77.32	144.58	169.86
Inventory Days	81.95	84.11	80.83	96.67	97.92
Payable days	139.04	176.65	125.94	135.45	159.68
Cash Conversion Cycle	41.56	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.